

## Supplementary Data

### Synthesis of Folate Derivative Phosphoramidites for siRNA Incorporation

Lidya Salim and Jean-Paul Desaulniers

Ontario Tech University, Faculty of Science, 2000 Simcoe Street North, Oshawa, ON L1G 0C5

#### Table of Contents

|  |    |
|--|----|
| <b>Procedures</b> .....  | 2  |
| <b>General materials and methods</b> .....   | 2  |
| <b>Compound and oligonucleotide characterization</b> .....                                     | 2  |
| <b>Statistical analysis</b> .....  | 2  |
| <b>Tables</b> .....  | 3  |
| <b>Table S1</b> Sequences and mass spectrometry data of modified oligonucleotide strands ..... | 3  |
| <b>Figures</b> .....   | 4  |
| <b>Figure S1</b> Structure of hydrolyzed product of compound <b>3</b> .....                    | 4  |
| <b>Figure S2</b> Analytical HPLC spectra of folate-modified oligonucleotide sense strands..    | 5  |
| <b>Figure S3</b> Inhibitory dose-response curves for modified siRNAs.....                      | 5  |
| <b>Figure S4</b> Melting temperature curve of modified siRNAs (Fol1-Fol4).....                 | 6  |
| <b>NMR Data</b> .....  | 7  |
| <sup>1</sup> H NMR of Compound <b>C</b> .....  | 7  |
| <sup>13</sup> C NMR of Compound <b>C</b> .....   | 7  |
| <sup>1</sup> H NMR of Compound <b>1</b> .....  | 8  |
| <sup>19</sup> F NMR of Compound <b>1</b> .....   | 8  |
| <sup>19</sup> F NMR of Compound <b>2</b> .....   | 9  |
| <sup>19</sup> F NMR of Compound <b>3</b> .....   | 10 |
| <sup>31</sup> P NMR of Compound <b>3</b> .....   | 10 |

## Procedures

### **General materials and methods**

All starting reagents and solvents were obtained from commercial sources and used without additional purification, unless otherwise indicated. Anhydrous  $\text{CH}_2\text{Cl}_2$  and  $\text{Et}_3\text{N}$  were purchased from Sigma-Aldrich and kept dry using a PureSolv 400 Solvent Purification System.

### **Compound and oligonucleotide characterization**

$^1\text{H}$ ,  $^{13}\text{C}$  and  $^{31}\text{P}$  NMRs were recorded in  $\text{DMSO-d}_6$ ,  $\text{CDCl}_3$  or  $\text{CD}_3\text{OD}$  using a Bruker Avance III NMR spectrometer. NMR spectra were processed with ACD/NMR Processor. High-performance liquid chromatography (HPLC) was performed on a Waters 1525 binary HPLC pump with a Waters 2489 UV/Vis detector, using a C18 4.6 mm x 150 mm reverse-phase column and eluting from 5 to 100% acetonitrile in a triethylamine-acetic acid (TEAA) buffer (pH 7.00) over 30 minutes. LC/MS chromatograms were acquired on an Agilent 6545 QTOF-MS with Agilent 1260 Infinity Binary Pump HPLC using a ZORBAX Eclipse Plus C18 2.1x100mm 1.8-Micron Agilent column and a mobile phase of 5 mM ammonium acetate buffer (pH 7)/acetonitrile (95:5). Oligonucleotide samples were prepared at a concentration of 0.01 O.D/ $\mu\text{L}$  with an injection volume of 20  $\mu\text{L}$ . Data were analyzed using Agilent Technologies MassHunter Workstation Qualitative Analysis Software (Qual. 10.0).

### **Statistical analysis**

The half-maximal inhibitory concentration ( $\text{IC}_{50}$ ) values were calculated after siRNA transfection in HeLa cells using GraphPad Prism 9 Software. Modified siRNAs were tested at ten concentrations following the carrier-free transfection protocol. Prism's variable slope (four-parameter) model was used for the analysis, and the resulting dose-response curves can be found in Supplementary Figure S3.


## Tables

**Table S1** Sequences and mass spectrometry data of modified oligonucleotide strands

| <i>Code</i> | <i>Sequence</i>                           | <i>Mass (predicted)</i> | <i>Mass (found)</i> |
|-------------|---|-------------------------|---------------------|
| <b>F1</b>   | 5' CUU ACG CUG AGU ACU UCG A <b>F</b> 3'  | 6580.9985               | 6580.4427           |
| <b>F2</b>   | 5' CUU ACG CUG AGU ACU <b>F</b> CG ATT 3' | 6886.3612               | 6886.4511           |
| <b>F3</b>   | 5' CUU ACG CUG <b>F</b> GU ACU UCG ATT 3' | 6859.0428               | 6858.7023           |
| <b>F4</b>   | 5' CUU ACG CU <b>F</b> AGU ACU UCG ATT 3' | 6844.0431               | 6844.3508           |



All strands code for firefly luciferase and correspond to the sense strand. **F** indicates the position of the folate modification.


## Figures




Exact Mass: 1134.3336  
Molecular Weight: 1134.9912

**Figure S1** Structure of hydrolyzed product of compound 3






**Figure S2** Analytical HPLC spectra of folate-modified oligonucleotide sense strands. Corresponding sequences can be found in Table S1. Eluting from 5% to 95% ACN in 0.1 M TEAA buffer (pH 7.0) over 30 minutes.




**Figure S3** Inhibitory dose-response curves for modified siRNAs in HeLa cells, following a carrier-free transfection protocol.




**Figure S4** Melting temperature curve of modified siRNAs (Fol1-Fol4)

### NMR Data


#### <sup>1</sup>H NMR of Compound C 400 MHz, CD<sub>3</sub>OD




#### <sup>13</sup>C NMR of Compound C 101 MHz, CD<sub>3</sub>OD



### <sup>1</sup>H NMR of Compound 1




### <sup>19</sup>F NMR of Compound 1






<sup>19</sup>F NMR of Compound 2



<sup>19</sup>F NMR of Compound 3#



<sup>31</sup>P NMR of Compound 3#

